NasdaqCM:PAVM.W

Stock Analysis Report

Executive Summary

PAVmed Inc. operates as a medical device company in the United States.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Share Price & News

How has PAVmed's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

PAVM.W

-0.003%

US Medical Equipment

1.3%

US Market


1 Year Return

62.4%

PAVM.W

11.9%

US Medical Equipment

5.9%

US Market


Shareholder returns

PAVM.WIndustryMarket
7 Day0%-0.003%1.3%
30 Day0%-3.0%-1.9%
90 Dayn/a-0.6%-1.8%
1 Year62.4%62.4%12.8%11.9%8.3%5.9%
3 Yearn/a69.6%64.5%45.6%36.2%
5 Yearn/a129.6%104.0%66.1%47.9%

Price Volatility Vs. Market

How volatile is PAVmed's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is PAVmed undervalued compared to its fair value and its price relative to the market?

17.3x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate PAVM.W's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate PAVM.W's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PAVM.W is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: PAVM.W is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate PAVM.W's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PAVM.W is overvalued based on its PB Ratio (17.3x) compared to the US Medical Equipment industry average (3.6x).


Next Steps

Future Growth

How is PAVmed forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

37.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PAVM.W is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PAVM.W is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PAVM.W is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if PAVM.W's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if PAVM.W's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Information is not available.


Next Steps

Past Performance

How has PAVmed performed over the past 5 years?

-52.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: PAVM.W is unprofitable, and losses have increased over the past 5 years at a rate of -52.4% per year.

Accelerating Growth: Unable to compare PAVM.W's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PAVM.W is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: PAVM.W has a negative Return on Equity (-291.3%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: PAVM.W is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: PAVM.W is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is PAVmed's financial position?


Financial Position Analysis

Short Term Liabilities: PAVM.W's short term assets ($9.4M) exceeds its short term liabilities ($5.8M)

Long Term Liabilities: PAVM.W has no long term liabilities


Debt to Equity History and Analysis

Debt Level: PAVM.W's debt to equity ratio (91.4%) is considered high

Reducing Debt: Insufficient data to determine if PAVM.W's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Information is not available.

Information is not available.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PAVM.W has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PAVM.W has sufficient cash runway for 1.201480 years if free cash flow continues to reduce at historical rates of -46.9% each year.


Next Steps

Dividend

What is PAVmed's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate PAVM.W's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate PAVM.W's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if PAVM.W's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PAVM.W's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PAVM.W's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of PAVmed's salary, the management and board of directors tenure and is there insider trading?

4.4yrs

Average management tenure


CEO

Lishan Aklog (52yo)

4.8yrs

Tenure

US$444,200

Compensation

Dr. Lishan Aklog, M.D, serves as the Chairman and Chief Executive Officer at PAVmed Inc. since June 26, 2014. He serves an Advisor at WI Harper Group. Dr. Aklog is a Founder and Principal of Pavilion Holdi ...


CEO Compensation Analysis

Information is not available.

Compensation vs Earnings: Lishan's compensation has been consistent with company performance over the past year.


Management Age and Tenure

4.4yrs

Average Tenure

53yo

Average Age

Experienced Management: PAVM.W's management team is considered experienced (4.4 years average tenure).


Board Age and Tenure

4.3yrs

Average Tenure

61yo

Average Age

Experienced Board: PAVM.W's board of directors are considered experienced (4.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Dennis McGrath (61yo)

    President

    • Tenure: 0yrs
    • Compensation: US$1.14m
  • Lishan Aklog (52yo)

    Chairman & CEO

    • Tenure: 4.8yrs
    • Compensation: US$444.20k
  • Brian deGuzman (53yo)

    Chief Medical Officer

    • Tenure: 4.4yrs
    • Compensation: US$399.00k
  • Shaun O'Neil

    Chief Commercial Officer

    • Tenure: 0.7yrs
  • Mike Havrilla

    Director of Investor Relations

    • Tenure: 0yrs

Board Members

  • Ron Sparks (63yo)

    Director

    • Tenure: 4.2yrs
    • Compensation: US$58.33k
  • David Weild (61yo)

    Director

    • Tenure: 4.1yrs
    • Compensation: US$70.00k
  • Todd Rosengart

    Member of Medical Advisory Board

    • Tenure: 4.3yrs
  • James Cox (74yo)

    Director

    • Tenure: 4.2yrs
    • Compensation: US$52.50k
  • Marc Gerdisch

    Member of Medical Advisory Board

    • Tenure: 4.3yrs
  • Lishan Aklog (52yo)

    Chairman & CEO

    • Tenure: 4.8yrs
    • Compensation: US$444.20k
  • Philip Stieg

    Member of Medical Advisory Board

    • Tenure: 4.2yrs
  • Al Chin

    Member of Medical Advisory Board

    • Tenure: 4.2yrs
  • Mike Glennon (52yo)

    Vice Chairman

    • Tenure: 4.4yrs
  • Timothy Murphy

    Member of Medical Advisory Board

    • Tenure: 4.3yrs

Company Information

PAVmed Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PAVmed Inc.
  • Ticker: PAVM.W
  • Exchange: NasdaqCM
  • Founded: 2014
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$29.857m
  • Shares outstanding: 27.14m
  • Website: https://www.pavmed.com

Number of Employees


Location

  • PAVmed Inc.
  • One Grand Central Place
  • Suite 4600
  • New York
  • New York
  • 10165
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PAVM.WNasdaqCM (Nasdaq Capital Market)WT EXP 012922USUSDJul 2016
PAVMNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJul 2016
1P5BST (Boerse-Stuttgart)YesCommon StockDEEURJul 2016

Biography

PAVmed Inc. operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; PortIO, an implantable intr ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/04/01 00:49
End of Day Share Price2019/01/25 00:00
Earnings2018/09/30
Annual Earnings2017/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.